BRPI1007046A2 - Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. - Google Patents
Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.Info
- Publication number
- BRPI1007046A2 BRPI1007046A2 BRPI1007046-0A BRPI1007046A BRPI1007046A2 BR PI1007046 A2 BRPI1007046 A2 BR PI1007046A2 BR PI1007046 A BRPI1007046 A BR PI1007046A BR PI1007046 A2 BRPI1007046 A2 BR PI1007046A2
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- prevent
- combination therapy
- metastatic cancer
- axl inhibitors
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037819 metastatic cancer Diseases 0.000 title 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14544809P | 2009-01-16 | 2009-01-16 | |
| US61/145,448 | 2009-01-16 | ||
| PCT/US2010/021275 WO2010083465A1 (en) | 2009-01-16 | 2010-01-15 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1007046A2 true BRPI1007046A2 (pt) | 2015-07-21 |
| BRPI1007046B1 BRPI1007046B1 (pt) | 2019-07-16 |
Family
ID=41683427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007046-0A BRPI1007046B1 (pt) | 2009-01-16 | 2010-01-15 | Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8546433B2 (pt) |
| EP (1) | EP2387395B1 (pt) |
| JP (2) | JP5858789B2 (pt) |
| CN (1) | CN102281875B (pt) |
| AU (1) | AU2010204578B2 (pt) |
| BR (1) | BRPI1007046B1 (pt) |
| CA (1) | CA2749843C (pt) |
| ES (1) | ES2528032T3 (pt) |
| PL (1) | PL2387395T3 (pt) |
| PT (1) | PT2387395E (pt) |
| RU (1) | RU2555326C2 (pt) |
| SG (1) | SG172997A1 (pt) |
| WO (1) | WO2010083465A1 (pt) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884119B2 (en) * | 2005-09-07 | 2011-02-08 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as Axl inhibitors |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| AU2007342005A1 (en) * | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| ES2404668T3 (es) | 2006-12-29 | 2013-05-28 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl |
| EP2114954B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| PT2078010E (pt) | 2006-12-29 | 2014-05-07 | Rigel Pharmaceuticals Inc | Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl |
| CA2704052C (en) * | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| HUE030912T2 (en) | 2008-02-15 | 2017-06-28 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases |
| JP5592884B2 (ja) * | 2008-07-09 | 2014-09-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール |
| US8431594B2 (en) | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
| JP4644273B2 (ja) * | 2008-07-15 | 2011-03-02 | 本田技研工業株式会社 | 車両周辺監視装置 |
| RU2555326C2 (ru) * | 2009-01-16 | 2015-07-10 | Риджел Фармасьютикалз, Инк. | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
| CA2775601C (en) | 2009-09-28 | 2017-10-03 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| GB201207722D0 (en) | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
| CN105764514B (zh) | 2013-11-27 | 2019-07-12 | 圣诺康生命科学公司 | 作为tam族激酶抑制剂的氨基吡啶衍生物 |
| EP3076966A2 (en) | 2013-12-02 | 2016-10-12 | BerGenBio AS | Use of kinase inhibitors |
| US20170027940A1 (en) * | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| US10028958B2 (en) * | 2014-04-19 | 2018-07-24 | Massachusetts Institute Of Technology | Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors |
| GB201420285D0 (en) | 2014-11-14 | 2014-12-31 | Bergenbio As | Process |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN106083764B (zh) * | 2016-07-11 | 2018-09-18 | 上海皓元生物医药科技有限公司 | 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| EP3703731A4 (en) * | 2017-11-04 | 2021-07-21 | Aravive Biologics, Inc. | METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS |
| MX2021003062A (es) | 2018-09-18 | 2021-05-27 | Signalchem Lifesciences Corp | Terapia combinada para tratar el cancer de sangre. |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| TW202304908A (zh) * | 2021-04-14 | 2023-02-01 | 日商衛材R&D企管股份有限公司 | 四氫吡啶并嘧啶化合物 |
| GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1403866A (en) * | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
| US4512992A (en) * | 1980-06-13 | 1985-04-23 | Burroughs Wellcome Co. | Treatment with dialkoxy pyridopyrimidine compounds |
| MX19185A (es) | 1989-01-20 | 1993-12-01 | Pfizer | Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas. |
| US6258360B1 (en) | 1989-05-04 | 2001-07-10 | Igen International, Inc. | Prodrugs activated by targeted catalytic proteins |
| WO1995003286A1 (en) | 1993-07-23 | 1995-02-02 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| CA2432870A1 (en) | 2000-12-22 | 2002-07-25 | Ronghui Lin | Substituted triazole diamine derivatives as kinase inhibitors |
| DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| TWI335221B (en) | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| CA2478338A1 (en) * | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| PL220850B1 (pl) | 2002-05-03 | 2016-01-29 | Janssen Pharmaceutica Nv | Kopolimer dwublokowy, kompozycja zawierająca składnik aktywny i jej zastosowanie oraz sposób jej wytwarzania |
| JP4483581B2 (ja) | 2002-08-06 | 2010-06-16 | 東レ株式会社 | 腎疾患治療又は予防剤及び腎疾患の診断方法 |
| AU2003286746A1 (en) * | 2002-10-29 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| EP1613625A1 (en) | 2003-03-14 | 2006-01-11 | AstraZeneca AB | Novel fused triazolones and the uses thereof |
| EP1632477B1 (en) | 2003-06-12 | 2017-03-01 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| AU2004263148B2 (en) | 2003-08-06 | 2008-08-21 | Vertex Pharmaceuticals, Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| CA2554925A1 (en) | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
| BRPI0507634A (pt) | 2004-02-11 | 2007-07-03 | Janssen Pharmaceutica Nv | processo para preparação de compostos triazóis substituìdos |
| US7754714B2 (en) | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| RU2007109073A (ru) | 2004-08-13 | 2008-09-20 | Дженентек, Инк. (Us) | Ингибиторы для атф-зависимого фермента на основе тиазола |
| MX2007003154A (es) | 2004-09-17 | 2007-05-15 | Vertex Pharma | Compuestos de diaminotriazol de utilidad como inhibidores de proteina quinasa. |
| ATE485042T1 (de) | 2004-10-21 | 2010-11-15 | Vertex Pharma | Triazole als hemmer von proteinkinasen |
| US20060166936A1 (en) | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
| KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US7884119B2 (en) * | 2005-09-07 | 2011-02-08 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as Axl inhibitors |
| JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| EP2007393B1 (en) | 2006-04-07 | 2013-08-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| FR2908131B1 (fr) | 2006-11-03 | 2009-01-09 | Univ Haute Alsace Etablissemen | Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique |
| JP2008130120A (ja) | 2006-11-17 | 2008-06-05 | Sharp Corp | 光ピックアップ装置 |
| US7879856B2 (en) * | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
| PT2078010E (pt) * | 2006-12-29 | 2014-05-07 | Rigel Pharmaceuticals Inc | Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl |
| EP2114954B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| ES2404668T3 (es) | 2006-12-29 | 2013-05-28 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl |
| AU2007342005A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| AU2008266290A1 (en) | 2007-06-15 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| CA2704052C (en) | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| HUE030912T2 (en) * | 2008-02-15 | 2017-06-28 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases |
| US8431594B2 (en) | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
| JP5592884B2 (ja) | 2008-07-09 | 2014-09-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール |
| RU2555326C2 (ru) | 2009-01-16 | 2015-07-10 | Риджел Фармасьютикалз, Инк. | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
-
2010
- 2010-01-15 RU RU2011132118/15A patent/RU2555326C2/ru active
- 2010-01-15 BR BRPI1007046-0A patent/BRPI1007046B1/pt active IP Right Grant
- 2010-01-15 ES ES10700686.8T patent/ES2528032T3/es active Active
- 2010-01-15 US US12/688,746 patent/US8546433B2/en active Active
- 2010-01-15 AU AU2010204578A patent/AU2010204578B2/en active Active
- 2010-01-15 PT PT107006868T patent/PT2387395E/pt unknown
- 2010-01-15 JP JP2011546409A patent/JP5858789B2/ja active Active
- 2010-01-15 SG SG2011051174A patent/SG172997A1/en unknown
- 2010-01-15 PL PL10700686T patent/PL2387395T3/pl unknown
- 2010-01-15 EP EP10700686.8A patent/EP2387395B1/en active Active
- 2010-01-15 CA CA2749843A patent/CA2749843C/en active Active
- 2010-01-15 CN CN201080004818.0A patent/CN102281875B/zh active Active
- 2010-01-15 WO PCT/US2010/021275 patent/WO2010083465A1/en not_active Ceased
-
2013
- 2013-06-03 US US13/908,874 patent/US20130338161A1/en not_active Abandoned
-
2014
- 2014-10-10 JP JP2014208912A patent/JP2015007135A/ja active Pending
-
2016
- 2016-03-22 US US15/077,648 patent/US20170042891A1/en not_active Abandoned
-
2019
- 2019-03-12 US US16/351,130 patent/US20190336500A1/en not_active Abandoned
-
2021
- 2021-06-18 US US17/351,996 patent/US20210379064A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2387395B1 (en) | 2014-10-15 |
| US8546433B2 (en) | 2013-10-01 |
| JP2015007135A (ja) | 2015-01-15 |
| US20100196511A1 (en) | 2010-08-05 |
| US20210379064A1 (en) | 2021-12-09 |
| SG172997A1 (en) | 2011-08-29 |
| CA2749843A1 (en) | 2011-07-22 |
| RU2011132118A (ru) | 2013-02-27 |
| US20170042891A1 (en) | 2017-02-16 |
| JP2012515225A (ja) | 2012-07-05 |
| US20190336500A1 (en) | 2019-11-07 |
| CN102281875B (zh) | 2017-09-22 |
| EP2387395A1 (en) | 2011-11-23 |
| AU2010204578A1 (en) | 2011-07-28 |
| ES2528032T3 (es) | 2015-02-03 |
| PT2387395E (pt) | 2015-02-04 |
| BRPI1007046B1 (pt) | 2019-07-16 |
| AU2010204578B2 (en) | 2016-05-12 |
| CA2749843C (en) | 2017-09-05 |
| JP5858789B2 (ja) | 2016-02-10 |
| HK1164146A1 (en) | 2012-09-21 |
| PL2387395T3 (pl) | 2015-03-31 |
| CN102281875A (zh) | 2011-12-14 |
| US20130338161A1 (en) | 2013-12-19 |
| WO2010083465A1 (en) | 2010-07-22 |
| RU2555326C2 (ru) | 2015-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2387395T3 (pl) | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym | |
| BRPI0921122A2 (pt) | sistema de terapia de próstata. | |
| BRPI0921422A2 (pt) | sistema de terapia de próstata. | |
| IT1400425B1 (it) | Modified snrnas for use in therapy. | |
| BRPI0921421A2 (pt) | sistema de terapia de próstata | |
| SI3192529T1 (sl) | Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev | |
| IL219992A0 (en) | Combination therapy for treating cancer and dianostic assays for use therein | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| SI2358697T1 (sl) | Spojine izoindolina za uporabo pri zdravljenju raka | |
| BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BR112013033940A2 (pt) | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer | |
| BR112012032962A2 (pt) | composição para utilização em um furo de poço, composição em gel para utilização em um furo de poço, e método. | |
| BR112012000254A2 (pt) | análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas. | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BR112012002797A2 (pt) | tratamento de câncer de próstata | |
| DK3791896T3 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
| BR112013022438A2 (pt) | forma de dosagem de dietilestilbestrol e uso para tratamento de câncer de próstota ou de mama | |
| BRPI0812040A2 (pt) | Indicações para terapia de anti-il-i-beta | |
| BRPI0822012A2 (pt) | Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer | |
| HK1212221A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/00 (1974.07), A61K 31/4196 (2000.01), A61P |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2010, OBSERVADAS AS CONDICOES LEGAIS |